8-K filing — Zymeworks Inc. (ZYME)
Filed: 2026-11-16 AccNo: 0001937653-26-000070 Size: 197 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Zymeworks Inc. has authorized a second 2026 share repurchase program, allowing for the buyback of up to $200 million of its common stock through 2028.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-16 AccNo: 0001937653-26-000070 Size: 197 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Citizens has increased its price target for Zymeworks shares from $32.00 to $39.00.
Zymeworks announced its financial results for the third quarter of 2026, reporting revenue of $256.5 million and earnings per share of $2.28, while raising its full-year 2026 financial guidance.